Kalytera Therapeutics Inc., of Vancouver, British Columbia, said it applied for a $5 million grant from the Israel Innovation Authority (IIA) to fund development of its portfolio of cannabidiol (CBD) prodrugs including: K-1012, indicated for acute respiratory distress syndrome; K-1022, indicated for ulcerative colitis; K-1032, indicated for acne vulgaris; and K-1052, being studied as an inducible nitric oxide synthase inhibitor, indicated for sepsis-associated renal failure and severe traumatic brain injury.